JP2017039714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017039714A5 JP2017039714A5 JP2016159454A JP2016159454A JP2017039714A5 JP 2017039714 A5 JP2017039714 A5 JP 2017039714A5 JP 2016159454 A JP2016159454 A JP 2016159454A JP 2016159454 A JP2016159454 A JP 2016159454A JP 2017039714 A5 JP2017039714 A5 JP 2017039714A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000003839 salts Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 206010030043 Ocular hypertension Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- -1 monofluoromethyl Chemical group 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 | ||
| JP2015160284 | 2015-08-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020148973A Division JP2020193235A (ja) | 2015-08-17 | 2020-09-04 | ヒドロキシトリアジン化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017039714A JP2017039714A (ja) | 2017-02-23 |
| JP2017039714A5 true JP2017039714A5 (enExample) | 2019-09-19 |
Family
ID=58052084
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016159454A Ceased JP2017039714A (ja) | 2015-08-17 | 2016-08-16 | ヒドロキシトリアジン化合物及びその医薬用途 |
| JP2020148973A Ceased JP2020193235A (ja) | 2015-08-17 | 2020-09-04 | ヒドロキシトリアジン化合物及びその医薬用途 |
| JP2022128590A Pending JP2022163169A (ja) | 2015-08-17 | 2022-08-12 | ヒドロキシトリアジン化合物及びその医薬用途 |
| JP2023207429A Active JP7640658B2 (ja) | 2015-08-17 | 2023-12-08 | ヒドロキシトリアジン化合物及びその医薬用途 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020148973A Ceased JP2020193235A (ja) | 2015-08-17 | 2020-09-04 | ヒドロキシトリアジン化合物及びその医薬用途 |
| JP2022128590A Pending JP2022163169A (ja) | 2015-08-17 | 2022-08-12 | ヒドロキシトリアジン化合物及びその医薬用途 |
| JP2023207429A Active JP7640658B2 (ja) | 2015-08-17 | 2023-12-08 | ヒドロキシトリアジン化合物及びその医薬用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (enExample) |
| EP (2) | EP4046991A1 (enExample) |
| JP (4) | JP2017039714A (enExample) |
| KR (1) | KR20180037270A (enExample) |
| CN (1) | CN108137515B (enExample) |
| AR (1) | AR105711A1 (enExample) |
| AU (1) | AU2016309337B2 (enExample) |
| BR (1) | BR112018001809A2 (enExample) |
| CA (1) | CA2992410A1 (enExample) |
| CL (1) | CL2018000430A1 (enExample) |
| CO (1) | CO2018002516A2 (enExample) |
| IL (1) | IL257559B (enExample) |
| MX (1) | MX375283B (enExample) |
| PE (1) | PE20180951A1 (enExample) |
| PH (1) | PH12018500181A1 (enExample) |
| SG (1) | SG11201800698VA (enExample) |
| TW (1) | TWI704139B (enExample) |
| WO (1) | WO2017030115A1 (enExample) |
| ZA (1) | ZA201801134B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN108137515B (zh) * | 2015-08-17 | 2021-07-06 | 日本烟草产业株式会社 | 羟基三嗪化合物和其医药用途 |
| US10710967B2 (en) * | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| WO2019002183A1 (de) * | 2017-06-26 | 2019-01-03 | Merck Patent Gmbh | Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen |
| CN119497709A (zh) * | 2022-07-06 | 2025-02-21 | Aska 制药株式会社 | 嘧啶衍生物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| DE19543730A1 (de) | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| JP3581103B2 (ja) | 1999-04-01 | 2004-10-27 | ファイザー・プロダクツ・インク | ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン |
| EP2529624A3 (en) | 2007-04-03 | 2013-03-13 | E. I. du Pont de Nemours and Company | Substituted benzene fungicides |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| KR101630256B1 (ko) | 2008-06-04 | 2016-06-15 | 가부시키가이샤 아데카 | 2,4,6-트리스(하이드록시페닐)-1,3,5-트리아진 화합물의 제조 방법 |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| US8952150B2 (en) | 2009-09-23 | 2015-02-10 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| WO2011048004A1 (en) | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) * | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| US9458174B2 (en) | 2012-05-23 | 2016-10-04 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN105586773A (zh) | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| CN108137515B (zh) * | 2015-08-17 | 2021-07-06 | 日本烟草产业株式会社 | 羟基三嗪化合物和其医药用途 |
-
2016
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 MX MX2018002044A patent/MX375283B/es active IP Right Grant
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Ceased
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh not_active IP Right Cessation
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja not_active Ceased
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en not_active Ceased
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US12492182B2/en active Active
- 2023-12-08 JP JP2023207429A patent/JP7640658B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039714A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| JP2020507589A5 (enExample) | ||
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| JP2016527217A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| JP2016522835A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2018534286A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2020520359A5 (enExample) | ||
| CN115315423A (zh) | 取代芳基类化合物 | |
| JP2016522254A5 (enExample) | ||
| PH12018500181A1 (en) | Hydroxytriazine compound and medical use thereof | |
| CN111788197A (zh) | 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途 | |
| JP2018062523A5 (enExample) | ||
| RU2010151142A (ru) | Замещенные хиназолины | |
| CN114072404A (zh) | Ret选择性抑制剂及其制备方法和用途 |